Bicycle Therapeutics(BCYC) - 2020 Q1 - Quarterly Report

Financial Performance - The company reported net losses of $11.3 million and $6.5 million for the three months ended March 31, 2020, and 2019, respectively, with an accumulated deficit of $111.9 million as of March 31, 2020[191]. - The net loss for the three months ended March 31, 2020, was $11.324 million, compared to a net loss of $6.503 million for the same period in 2019, representing an increase of $4.821 million[219]. - For the three months ended March 31, 2019, the net loss was $6.5 million, with net cash used in operating activities totaling $2.4 million[232]. - Other income (expense), net increased by $3.3 million in the three months ended March 31, 2020, with a recognition of $0.2 million of interest income compared to a $3.2 million expense in the same period in 2019[225]. Revenue and Funding - The company has not generated any revenue from product sales and does not expect to do so for the foreseeable future, relying primarily on collaboration revenues[197]. - The company has not generated any revenue from product sales since inception and does not expect to do so for several years[226]. - Total gross proceeds from the sale of ADSs, ordinary shares, and convertible preferred shares reached $193.0 million, including $30.0 million from Genentech and $9.4 million from AstraZeneca[228]. - The company has raised gross proceeds of $193.0 million from the sale of ADSs, ordinary shares, and convertible preferred shares since its inception in 2009 through March 31, 2020[190]. Expenses and Costs - Research and development expenses increased by $1.5 million to $7.774 million for the three months ended March 31, 2020, compared to $6.276 million for the same period in 2019, primarily due to increased clinical program expenses and personnel-related costs[221]. - Total operating expenses rose to $12.772 million for the three months ended March 31, 2020, compared to $9.678 million for the same period in 2019, reflecting a $3.094 million increase[219]. - General and administrative expenses increased by $1.6 million to $4.998 million for the three months ended March 31, 2020, compared to $3.402 million for the same period in 2019, primarily due to increases in personnel costs, professional fees, and share-based compensation[224]. - The company anticipates an increase in general and administrative expenses as it expands its headcount and incurs costs associated with being a public company[210]. Clinical Development - The company is currently enrolling patients in a Phase I/II clinical trial for BT5528 in the United States, while enrollment for BT1718 has paused due to the COVID-19 pandemic[186]. - The lead product candidate, BT1718, is being developed for tumors expressing MT1-MMP and is currently in a Phase I/IIa clinical trial[183]. - The company expects significant increases in expenses and capital requirements as it advances clinical trials for product candidates BT1718 and BT5528, and progresses preclinical development for BT8009, BT7480, BT7401, and BT7455[192]. - The company expects substantial increases in expenses related to ongoing activities, particularly for preclinical and clinical trials of product candidates BT1718 and BT5528[235]. COVID-19 Impact - The company has established a cross-functional task force to address the impact of the COVID-19 pandemic, with limited financial impacts observed so far[185]. - The company anticipates potential disruptions to its supply chain and operations due to the COVID-19 pandemic, which could affect clinical trial materials and product manufacturing[187]. - The COVID-19 pandemic has caused significant disruptions in global financial markets, potentially affecting the company's ability to access additional capital[237]. - The company anticipates needing significant additional funding to support ongoing operations and product development, especially in light of the COVID-19 pandemic's impact on financial markets[237]. Future Outlook - The company expects expenses to increase substantially as it advances preclinical activities and clinical trials for product candidates, including BT1718 and BT5528[235]. - Existing cash is expected to fund operating expenses for at least the next twelve months, but this is based on assumptions that may prove incorrect[238]. - The company plans to finance cash needs through equity offerings, debt financings, and collaborations, which may dilute existing shareholders' interests[241]. - The company aims to expand its infrastructure and facilities to support a growing employee base and enhance research and development capabilities[236]. Collaboration and Agreements - The company collaborates with biopharmaceutical companies in various therapeutic areas beyond oncology, including anti-bacterial and cardiovascular indications[184]. - The company entered into a Clinical Trial and License Agreement with Cancer Research Technology Limited and Cancer Research UK for the Phase I/IIa clinical trial of BT1718, with milestone payments totaling $50.9 million upon achieving certain milestones[203]. - Collaboration revenues decreased by $5.3 million to $1.129 million for the three months ended March 31, 2020, primarily due to a $6.0 million decrease from the collaboration with Sanofi[220]. Taxation and Corporate Structure - The company is subject to corporate taxation in the U.S. and U.K., but has not paid U.K. corporation tax due to ongoing losses since inception[212]. - The U.K. research and development tax credit is recorded as a reduction to research and development expenses, benefiting the company financially[213]. - The company is classified as an "emerging growth company" and will remain so until certain financial thresholds are met, including total annual gross revenue of at least $1.07 billion[245]. - The company plans to rely on exemptions provided by the JOBS Act, which includes reduced reporting requirements for a period of five years following its IPO[246].